Abstract: An emesis waste disposal system with both an outer bag and an inner bag. The inner bag is releasably attached within an inside of the outer bag, and disposed in a ready, open position within the outer bag. Advantageously an edge of the inner bag is folded out over a lip of the outer bag, to receive waste into the inner bag without soiling the outer bag. Optionally, the inner bag is releasably attached within an inside of the outer bag with a removable fastener such as a tin tie, hook and loop pile, or snap set.

Abstract: A pharmaceutical agent for treating an amyloid disease such as Alzheimer's Disease that includes a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus Uncaria, species tomentosa, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

Abstract: A pharmaceutical composition, or pharmaceutical agent for treating A? amyloidosis in a patient, having at least one selected laminin peptide or fragment thereof from the group AG73 (SEQ ID NO:1), C-16 (SEQ ID NO:2), A-13 (SEQ ID NO:3), HA3G47 (SEQ ID NO:4), HA3G58 (SEQ ID NO:5), HA3G67 (SEQ ID NO:6), HA3G74 (SEQ ID NO:7), HA3G76 (SEQ ID NO:8), HA3G79 (SEQ ID NO:9), HA3G83 (SEQ ID NO:10), A4G82 (SEQ ID NO:11), A5G15 (SEQ ID NO:12), A5G56 (SEQ ID NO:13), A5G80 (SEQ ID NO:14), A5G81 (SEQ ID NO:15), A5G82 (SEQ ID NO: 16), A5G84 (SEQ ID NO:17), A5G101 (SEQ ID NO:18), and A5G109 (SEQ ID NO:19) (Sequence Group A); and a method for enhancing A? amyloid fibril formation, or of forming amyloid-plaque like deposits in vitro, including incubating A? 1-40 or A? 1-42 with a selected laminin-derived polypeptide from the group A-13 (SEQ ID NO:3), HA3G47 (SEQ ID NO:4), HA3G58 (SEQ ID NO:5), HA3G83 (SEQ ID NO:10), LAM-L (SEQ ID NO:20), A4G10 SEQ ID NO:21), A4G46 (SEQ ID NO:22), A4G47 (SEQ ID NO:23), A4G84 (SEQ ID NO:24), A4G92

Abstract: Assay-guided affinity fractionation and reverse phase high pressure liquid chromatography (HPLC) methodology to isolate, test and characterize the most active water-soluble ingredients within Cat's Claw, or Uncaria tomentos. These components appear to account for the majority of the amyloid or A? fibrillogenesis inhibitory activity. Individual fractions and/or compounds as isolated by HPLC are tested in relevant in vitro and/or animal models, and found to consistently demonstrate inhibition of amyloid or A? fibrillogenesis. Related extraction methods are disclosed.

Abstract: A novel real time internet communication system is disclosed. It is a novel way for users to collaborate on the fly, and without having to own or download any programs that then stay resident on the user's computer. It is marketed under a novel business system that makes highly productive software available to businesses and end users, but which is not purchased by customers or end users, has no conventional distribution system, and never requires update, installation or rollout by the customer or end user.

Abstract: An improved turbine engine topology, wherein the improvement comprises a repositioning, with respect to a conventional intercooled regenerative turbine engine topology, of exhaust gas output from a low pressure turbine stage to a regenerator, to an exhaust gas output from a high pressure turbine stage to the regenerator. The engine topology may additionally employ, as an intermediate stage between the high pressure turbine and the low pressure turbine, a feedback control system, whereby the exhaust gas output from the high pressure turbine stage to the regenerator flows through the feedback control. The engine topology may advantageously also employ an additional cooler and an additional exhaust gas output in the feedback control, whereby exhaust gas flows from the feedback control through the additional cooler to a high pressure compressor stage, or the exhaust gas can flow from the feedback control through a bottoming cycle to the high pressure compressor stage.

Abstract: A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises a glucose monosaccharide containing at least one anionic group, or a pharmaceutically acceptable salt thereof. The agent is directed to amyloid diseases in general and to Alzheimer's disease in particular. Methods of treating an amyloid disease in a patient by administering therapeutically effective amounts of a glucose monosaccharide containing at least one anionic group are also presented.

Abstract: An improved turbine engine topology, wherein the improvement comprises a repositioning, with respect to a conventional intercooled regenerative turbine engine topology, of exhaust gas output from a low pressure turbine stage to a regenerator, to an exhaust gas output from a high pressure turbine stage to the regenerator. The engine topology may additionally employ, as an intermediate stage between the high pressure turbine and the low pressure turbine, a feedback control system, whereby the exhaust gas output from the high pressure turbine stage to the regenerator flows through the feedback control. The engine topology may advantageously also employ an additional cooler and an additional exhaust gas output in the feedback control, whereby exhaust gas flows from the feedback control through the additional cooler to a high pressure compressor stage, or the exhaust gas can flow from the feedback control through a bottoming cycle to the high pressure compressor stage.

Abstract: An artificially enhanced or induced windsource wind accessory device for use with a tethered display device. The wind accessory device has a hollow air director, a natural air intake port, a generated wind port, and an air output port to the banner. Generated wind intake air activates a blocker to close the natural wind intake port. Optionally, the banner is lighted from a light source disposed inside the air director. In an alternate embodiment, the wind accessory device has a perforated tube connected to a wind source and the tube has multiple perforations along the section adjacent to the banner and the perforations face the banner.

Abstract: A method of inhibiting amyloid formation, deposition, accumulation, or persistence, or amyloid protein-amyloid protein interactions, amyloid-proteoglycan interactions, amyloid-PG/GAG interactions and/or amyloid-glycosaminoglycan interactions, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in Alzheimer's Disease in a mammalian subject. In the method a therapeutically effective amount of plant matter from the genus Uncaria, species tomentosa is administered, preferably from the inner bark or root tissue of Uncaria tomentosa.

Abstract: A precisely measured removable cover for reusable beverage containers. A covering of independently resilient material is precisely cut to fit a given size and shape of pot, and the material has imprinted on it a desired promotional or advertising message and/or graphics. The covering material is removably fastened with releasable closures to the outside of the pot in such a way as not to impair significantly the natural independent resiliency of the material. Thus, dents in the pot do not generally show in the covering surface because it retains its independent resiliency, even if the blow was delivered through the covering surface. Messages may be changed as often as suits the promotional and decorative needs of the owner of the pot, so the display surface is always timely and in top condition. An optional “window” permits display of interchangeable labels on the inside of the covering.

Abstract: A settling tank for clarifying washing fluids with one or more walls disposed within the tank, each wall having a plurality of passages and defining a settling chamber. Preferably there is a top mounted fluid runoff opening into the tank disposed above the innermost settling chamber and at least one pump inlet disposed in an upper part of the tank outside the outermost settling chamber. Passages in the inner wall are in a lower region of the wall, and the passages in the second wall are in an upper region of the wall, and at least some of the passages are hooded to enhance a flow velocity change for fluid passing through the passages. There is optionally a sump pump having a one way valve for discharging sump sediment from the sump into a portable waste can. There is also preferably a sump tube generally curved upwardly and away from a bottom of the sump, and to which the pump is connected.

Abstract: A gore cutter with a principal roller and a pinch roller, a material feed roller and a take up roller. The take up roller has a tension bar transducer for controlling the rate of take up and feed of a material to be cut over the roller. A movable laser cutting assembly is controlled to move along a path parallel to a central axis of the principal roller.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and a amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition.

Abstract: An isolated polynucleotide that is a splice variant of perlecan formed by a partial or complete deletion of a number of exons within domain I of perlecan, the number of exons deleted from domain I numbering less than the number of exons in domain I. An isolated polynucleotide that is a splice variant of perlecan formed by an insertion of nucleotides within domain I of perlecan. A method of detection and/or quantitation of a splice variant of perlecan domain I gene in a sample, the method comprising making complimentary DNA (cDNA) from messenger RNA (mRNA) in the sample, amplifying portions of the cDNA corresponding to the perlecan gene or parts thereof and detecting and quantifying the amplified cDNA in order to detect or quantify the splice variant.

Abstract: Innovative disposable thoracostomy and cricothyrotomy trocar systems and new and improved methods for emergency management of upper airway obstructions and chest injuries are disclosed.

Abstract: An improved drum pedal having movable head pivots, a clutch on a beater connect, a compression spring with a bearing mount, a circular ramp (MemoryLock release) for cam adjustment of the drum rim clamp, and a cog belt/cog wheel linkage combination.

Abstract: The method of the invention in one aspect involves electronic power control by varying the amplitude of an electrical power supply voltage, independent of frequency, whereby the output frequency will always be the same as the input frequency. An electrical circuit apparatus for accomplishing this function in a preferred embodiment is also disclosed herein. The preferred circuitry of this aspect of the invention uses four solid state switches, such as IGBT's, four diodes, an inductor, input and output filters and novel controlling circuitry. The controller apparatus and methods of the invention may be used to implement all otherwise conventional converter types, buck, boost, and inverting (and duals of these) versions to obtain different regulating characteristics, including galvanic isolation of the output from the input.

Abstract: A method for treating brain amyloid deposits and the symptoms and conditions associated with brain amyloid deposits using the plant Uncaria tomentosa and extracts therefrom

Abstract: In vivo assays for selecting candidate therapeutics for inhibiting amyloidoses, such as congophilic and fibrillar &bgr;/A4 amyloid deposition in brain. A candidate reagent is administered to a first rat in a first infusate comprising &bgr;/A4 peptide and perlecan by continuous infusion for at least one week into hippocampus. The candidate reagent is selected as a candidate therapeutic for inhibiting congophilic and fibrillar &bgr;/A4 amyloid deposition in brain if the first infusate diminishes congo red and thioflavin S staining indicative of amyloid deposition adjacent to the infusion site, as compared with a second rat receiving a second infusate consisting essentially of &bgr;/A4 peptide and perlecan.